Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NSCLC, metastatic 2

4406 - Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro)


21 Oct 2018


Poster Discussion session - NSCLC, metastatic 2



Tumour Site


Roy S. Herbst


R.S. Herbst1, E.B. Garon2, D. Kim3, B. Chul Cho4, J.L. Pérez Gracia5, J. Han6, C. Dubos Arvis7, M. Majem8, M. Forster9, I. Monnet10, S. Novello11, Z. Szalai12, M.A. Gubens13, W. Su14, G.L. Ceresoli15, A. Samkari16, E. Jensen16, G.M. Lubiniecki16, P. Baas17

Author affiliations

  • 1 Medical Oncology, Yale University School of Medicine Medical Oncology, 06520-8032 - New Haven/US
  • 2 David Geffen School Of Medicine At The University Of California, Los Angeles, 90095 - Santa Monica/US
  • 3 Seoul National, University Hospital, 101 - Seoul/KR
  • 4 Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 5 Medical Oncology, Clinica Universidad de Navarra, 31008 - Pamplona/ES
  • 6 Medical Oncology, National Cancer Center (Korea), Goyang-si/KR
  • 7 Oncology, Centre François Baclesse, Caen/FR
  • 8 Medical Oncology, Hospital de la Santa Creu I Sant Pau, Barcelona/ES
  • 9 Oncology, University College Hospital, London/GB
  • 10 Oncology, Centre Hospitalier Intercommunal Créteil, Créteil/FR
  • 11 University Of Turin, Azienda Ospedaliero-Universitaria San Luigi, Orbassano/IT
  • 12 Pulmonological Department, Petz Aladár Megyei Oktató Kórház, Gyor/HU
  • 13 University Of California, San Francisco, San Francisco/US
  • 14 Oncology, National Cheng Kung University Hospital, Tainan/TW
  • 15 Pneumological And Urological Oncology, Cliniche Humanitas Gavazzeni, 24125 - Bergamo/IT
  • 16 Oncology, Merck & Co., Inc., Kenilworth/US
  • 17 The Netherlands Cancer Institute, The Academic Medical Hospital Amsterdam, Amsterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4406


KEYNOTE-010 (NCT01905657) is a global, open-label, phase 2/3 study of pembro 10 mg/kg or 2 mg/kg Q3W vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥1%. Pembro improved OS vs docetaxel in the PD-L1 TPS ≥1% and ≥50% co-primary analyses (median follow-up, 13.1 mo), with no difference between pembro doses. We present updated OS for the study overall and results for pts who completed 35 cycles (~2 y) of pembro.


Pts >18 years with previously treated advanced NSCLC with PD-L1 TPS ≥1% were randomized (1:1:1) to pembro 10 mg/kg or 2 mg/kg Q3W, or docetaxel 75 mg/m2 Q3W. Pts received pembro for 35 cycles or until disease progression/intolerable toxicity. After the primary analysis, crossover from docetaxel to pembro was allowed. Response was assessed every 9 wk (RECIST 1.1 by independent central review), and survival every 2 mo after treatment ended. OS was a primary endpoint. Pembro doses were pooled.


As of March 16, 2018, median (range) follow-up was 42.5 (35.2–53.2) mo. Among all pts (N=1033), pembro improved OS vs docetaxel (HR, 0.69; 95% CI, 0.60–0.80; P<0.00001), with median (95% CI) OS of 11.8 (10.4–13.1) mo vs 8.4 (7.6–9.5) mo, and 36-mo OS rate of 23% vs 11%, respectively. Incidence of grade 3–5 treatment-related AEs was similar to the primary analysis: 16% of pts in the pembro group and 36% in the docetaxel group had grade 3–5 treatment-related AEs (0.7% and 1.6%, respectively, had grade 5 AEs). 22% and 9% of pts, respectively, had immune-mediated AEs and infusion reactions. Among 79 pts who completed 35 pembro cycles, the 36-mo OS rate was 99% and 95% had PR/CR as best response. Response was ongoing in 44 pts (59%); median duration of response was not reached (range, 1+ to 46+ mo). 25 of 79 pts (32%) had PD (investigator review) after stopping 35 cycles of treatment, 13 of whom started second course pembro.


With an additional 30-mo follow-up from the primary analyses, pembro continued to prolong OS vs docetaxel in pts with previously treated, PD-L1–expressing advanced NSCLC, with manageable long-term safety. Most pts who completed 2 y of pembro had durable response, and the majority of pts who had PD after stopping 35 cycles of pembro were able to receive a second course of pembro.

Clinical trial identification

ClinicalTrials.gov, NCT01905657

Editorial Acknowledgement

Medical writing and editorial assistance was provided by C4 MedSolutions, LLC (Yardley, PA), a CHC Group company. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.